Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned ( @:@:@ ) to receive up to @ courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel , carboplatin , and mapatumumab ( @ mg/kg or @ mg/kg ) .